KRAS and biliary tract neoplasm: Recently, Okamura et al. identified mutations in TP53 (38%), KRAS (28%), and PIK3CA (14%) for ctDNA in biliary tract cancers and demonstrated that 76% of biliary tract cancer had at least one characterized alteration in ctDNA.